New vaccine may be a treatment for KRAS-mutated cancers. KRAS-mutated cancers such as colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are among the leading causes of cancer death. These cancers are considered incurable when tumor DNA or protein recurs after curative therapy. Therefore the discovery of alternative treatments for KRAS-mutated cancers is critical. One promising option is ELI-002 2P, an off-the-shelf amphiphilic (Amph), lymph node-directed vaccine that targets KRAS-driver oncogenes in solid tumors. In a first-in-human phase 1 trial (AMPLIFY-201), ELI-002 2P was successfully delivered as a monotherapy to the lymph nodes of PDAC and CRC patients who'd previously undergone surgery and chemotherapy. This triggered an immune response in 84% of patients with minimal residual disease after resection. T cell responses correlated with reduction and clearance of tumor biomarkers, and, in patients with above-median T cell responses, relapse-free survival was significantly improved. The recommended phase 2 dose of ELI-002 2P was safe and well tolerated. Although further evaluation in a larger, more diverse patient population is needed, these findings provide proof of concept for the safety and immunogenicity of lymph-node-targeting Amph vaccines for KRAS-mutated cancers. ELI-002 is proceeding with a phase 1 and randomized phase 2 study (AMPLIFY-7P).